1. T. Battelino, R.M. Bergenstal, Continuous Glucose Monitoring-Derived Data Report-Simply a Better Management Tool. Diabetes Care 43(10), 2327–2329 (2020) https://pubmed.ncbi.nlm.nih.gov/32958615/

Article  PubMed  Google Scholar 

2. T. Battelino, T. Danne, R.M. Bergenstal, S.A. Amiel, R. Beck, T. Biester et al., Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 42(8), 1593–603. (2019). Available from https://dx.doi.org/10.2337/dci19-0028

Article  PubMed  PubMed Central  Google Scholar 

3. De M. Bock, J.C. Agwu, M. Deabreu, K. Dovc, D.M. Maahs, M.L. Marcovecchio et al., International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets. Horm. Res. Paediatr. 97(6), 546–554 (2025)

Google Scholar 

4. G. Díaz-Soto, P. Pérez-López, P. Férnandez-Velasco, M. Nieto de la Marca, de la O. Delgado, E. del Amo S et al., Glycemia Risk Index Assessment in a Pediatric and Adult Patient Cohort With Type 1 Diabetes Mellitus. J Diabetes Sci Technol. 18(5), 1063. (2025). Available from https://pmc.ncbi.nlm.nih.gov/articles/PMC11418463/

5. C. Piona, M. Marigliano, E. Mozzillo, Di F. Candia, A. Zanfardino, D. Iafusco et al., High Glycemic Variability Is Associated with Worse Continuous Glucose Monitoring Metrics in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr 94(9–10), 369–73. (2021) Available from https://pubmed.ncbi.nlm.nih.gov/34915493/

Article  PubMed  CAS  Google Scholar 

6. C. Fabris, S.D. Patek, M.D. Breton, Are Risk Indices Derived From CGM Interchangeable With SMBG-Based Indices? J Diabetes Sci Technol. 10(1), 50. (2015). Available from https://pmc.ncbi.nlm.nih.gov/articles/PMC4738215/

Article  PubMed  PubMed Central  Google Scholar 

7. Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, et al. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. J Diabetes Sci Technol. 17(5), 1226–1242. (2023). Available from: https://pubmed.ncbi.nlm.nih.gov/35348391/

8. He BB, Liu ZZ, Xu RY, Fan L, Guo R, Deng C, et al. Glycated hemoglobin is not enough: The role of glycemia risk index for glycemic control assessment in type 1 diabetes. World J Diabetes. 16(6), 104024. (2025). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12179899/

9. Lee MH, Vogrin S, Jones TW, O’Neal DN. Hybrid Closed-Loop Versus Manual Insulin Delivery in Adults With Type 1 Diabetes: A Post Hoc Analysis Using the Glycemia Risk Index. J Diabetes Sci Technol. 2024 18(4), 764–770. Available from: https://journals.sagepub.com/doi/abs/10.1177/19322968241231307

10. Resmini E, Zarra E, Dotti S, Rotondi G, Cornaghi AV, Madaschi S, et al. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience. Eur J Med Res. 29(1), 365. (2024). Available from: https://pubmed.ncbi.nlm.nih.gov/39004734/

11. Committee ADAPP, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 14. Children and Adolescents: Standards of Care in Diabetes—2024. Diabetes Care. 47(Supplement_1), S258–81. (2024). Available from: https://dx.doi.org/10.2337/dc24-S014

12. Haller MJ, Bell KJ, Besser REJ, Casteels K, Couper JJ, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Horm Res Paediatr. 97(6), 529–545. (2025). Available from: https://pubmed.ncbi.nlm.nih.gov/39662065/

13. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 39(2), 175–91. (2007 ) Available from: https://pubmed.ncbi.nlm.nih.gov/17695343/

14. Bukara-Radujkovic G, Miljkovic V. Glycemic variability through the perspective of the glycemia risk index and time in range and their association with glycated hemoglobin A1c in pediatric patients on sensor-augmented pump therapy. Front Endocrinol (Lausanne). 15, 1388245. (2024). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11217307/

15. Szymezak J, Leroy N, Lavalard E, Gillery P. Evaluation of the DCA Vantage analyzer for HbA1c assay. Clin Chem Lab Med. 46(8), 1195–8. (2008) Available from: https://pubmed.ncbi.nlm.nih.gov/18588431/

16. Piona C, Marigliano M, Roncarà C, Mozzillo E, Di Candia F, Zanfardino A, et al. Glycemia Risk Index as a Novel Metric to Evaluate the Safety of Glycemic Control in Children and Adolescents with Type 1 Diabetes: An Observational, Multicenter, Real-Life Cohort Study. Diabetes Technol Ther. 25(7), 507–512. (2023) Available from: https://pubmed.ncbi.nlm.nih.gov/37155332/

17. Dovc K, Lanzinger S, Cardona-Hernandez R, Tauschmann M, Marigliano M, Cherubini V, et al. Association of Achieving Time in Range Clinical Targets With Treatment Modality Among Youths With Type 1 Diabetes. JAMA Netw Open. 6(2), e230077. (2023). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9941889/

18. Babiker A, Alammari N, Aljuraisi A, Alharbi R, Alqarni H, Masuadi E, et al. The Effectiveness of Insulin Pump Therapy Versus Multiple Daily Injections in Children With Type 1 Diabetes Mellitus in a Specialized Center in Riyadh. Clin Med Insights Endocrinol Diabetes. 15, 11795514221128496 (2022). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9597023/

19. Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A View Beyond HbA1c: Role of Continuous Glucose Monitoring. Diabetes Therapy. 10(3), 853–63. (2019). Available from: https://link.springer.com/article/10.1007/s13300-019-0619-1

20. Committee ADAPP, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024. Diabetes Care. 47(Supplement_1), S111–25. (2024). Available from: https://dx.doi.org/10.2337/dc24-S006